What's the Mystery Behind Kali Inc (OTCMKTS:KALY)?
January 31 2019 - 10:39AM
InvestorsHub NewsWire
What’s the Mystery Behind Kali Inc
(OTCMKTS:KALY)?
January 19, 2019 -- By James Hudson -- Original
Source: Oracledispatch
Shares of Kali Inc (OTCMKTS:KALY) have
been a real mystery to the trading world, seemingly coming out of
nowhere back in December to mount 3x gains on strong volume. The
story here is about a partnership and a move into the CBD space.
And to further develop that story, the company just announced a new
25 mg CBD Extract formulation for beverage infusion.
According to the release, “KALY owns and manages a patented
cannabis extraction process. PURA has licensed the KALY
patent for beverage infusion. PURA currently produces EVERx
CBD Sports Water infused with 10 mg of CBD. Together KALY and
PURA are designing a new private labeled CBD infused beverage for
Generex Biotechnology, Inc. (OTCBB:
GNBT). In response to feedback from PURA’s EVERx
distributors, KALY and PURA are now working together to refine a
new 25 mg CBD extract formulation.”
Kali Inc (OTCMKTS:KALY)
trumpets itself as a developer and owner of a patented cannabis
extraction process – U.S. Patent No. 9,199,960 entitled “METHOD AND
APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE
CANNABIS PLANT.”
This came about on November 15, 2018, with the acquisition of
NCM Biotech.
With the patented intellectual property (IP), to include the
existing and ongoing research and development acquired from NCM
Biotech, Kali now focuses on the development of pharmaceuticals to
treat various illnesses, diseases and chronic pain as a symptom of
various diagnoses. Kali also concentrates on the development of
health and wellness therapies.
NCM Biotech (acquired by Kali-Extracts) in collaboration with
Beech Tree Labs, Inc. (BTL) of Providence, Rhode Island, conducted
a series of in vitro genomic experiments to evaluate the potential
of cannabis extracts derived from KALY’s patented extraction
process in the treatment of respiratory diseases. The
experiments were designed to evaluate pure cannabis extracts and
cannabis extracts in combination with other therapies in the
treatment of chronic obstructive pulmonary disease (COPD) and
Asthma. There are a significant number of genes associated
with COPD and Asthma. The experiments evaluated the ability
of various formulations to change Asthma or COPD associated gene
expressions in human small airway epithelial cells. A
cannabis extract alone demonstrated remarkable activity in gene
arrays by up- or down-regulating individual genes by as much as
200-fold. Genes appearing especially sensitive to the
introduction of cannabis extract were associated with inflammation,
healing and cancer inhibition. Results from this series of
experiments provided a baseline for comparison with data from
subsequent studies.
In addition, KALY has entered into a joint venture agreement
named US Cannabis Health with Puration, Inc. (USOTC:
PURA), and Nouveau Pharmaceuticals, Inc.
(USOTC:
NOUV) to combine their respective resources for the
specific purpose of developing partnerships with major
pharmaceutical companies to produce medical cannabis therapies.
As noted above, KALY just announced a new 25 mg CBD Extract
formulation for beverage infusion. In all, we’ve witnessed 5%
tacked on to share pricing for the stock in the past week.
Furthermore, the name has benefitted from a jump in recent trading
volume to the tune of 47% beyond its prior sustained average
level.
“Through the retail outlets our distributors serve, we are
getting feedback that there is an unserved demand for CBD infused
beverages with 25 mg of CBD,” said Brian Shible, CEO of PURA.
“Not many beverages even have the 10 mg concentration we
currently deliver. Next to no beverage comes with 25
mg. We believe we can deliver 25 mg and still maintain our
clean refreshing taste. We are considering introducing this
first 25 mg beverage exclusively under the Generex label.”
At this time, carrying a capital value in the market of
$16.19M, KALY has virtually no cash on the books,
which compares with about $185K in total current liabilities. KALY
is pulling in trailing 12-month revenues of $119K. In addition, the
company is seeing major top-line growth, with y/y quarterly
revenues growing at 205.1%. This is an exciting story, and we look
forward to a follow-up chapter as events
transpire. Sign-up for continuing coverage on shares
of $KALY stock, as well as other hot stock picks, get our free
newsletter today and get our next breakout pick!
Disclosure: we hold no position in $KALY, either long or
short, and we have not been compensated for this article.
Original Source: Oracledispatch
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Sep 2023 to Sep 2024